

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2007; month=12; day=4; hr=13; min=57; sec=54; ms=828; ]

=====

Application No: 10557583 Version No: 1.0

Input Set:

Output Set:

Started: 2007-11-14 15:54:46.973  
Finished: 2007-11-14 15:54:47.974  
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 1 ms  
Total Warnings: 12  
Total Errors: 2  
No. of SeqIDs Defined: 12  
Actual SeqID Count: 12

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

# SEQUENCE LISTING

<110> DE ROUGE, BONABES  
MABROUK, KAMEL  
SABATIER, JEN-MARC

<120> MODIFIED ANTIVIRAL PEPTIDES WITH INCREASED ACTIVITY AND  
CELL MEMBRANE AFFINITY

<130> 20647/0203621-US0

<140> 10557583

<141> 2007-11-14

<150> PCT/EP04/005563

<151> 2004-05-20

<150> GB 0311565.6

<151> 2003-05-20

<150> GB 0319514.6

<151> 2003-08-20

<160> 12

<170> PatentIn Ver. 3.3

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 1

Gly Pro Gly Arg

1

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2

Ile Gly Pro Gly Arg

1

5

<210> 3

<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (2)..(3)  
<223> variable amino acid

<400> 3  
Ile Xaa Xaa Gly Pro Gly Arg  
1 5

<210> 4  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 4  
Gly Pro Gly Arg Ala Phe  
1 5

<210> 5  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (8)  
<223> beta-Ala  
  
<400> 5  
Lys Lys Lys Lys Lys Lys Lys Ala  
1 5

<210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence  
  
<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 6

Arg Gln Gly Tyr

1

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 7

Arg Gln Gly Tyr Ser Pro Leu

1

5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 8

Arg Gln Gly Tyr Ser Pro

1

5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 9

Arg Gln Gly Tyr Ser

1

5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

peptide

<400> 10

Gly Arg Gly Arg Ala  
1 5

<210> 11

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 11

Lys Lys Lys Lys Lys Lys Lys  
1 5

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 12

Gly Pro Gly Arg Ala  
1 5